-
While you may be comfortable with menstrual suppression through use of continuous oral contraceptives (OCs), are your patients? According to results from a national survey, more than 66% of women say that they are interested in suppressing their menstrual periods, but many of them aren't sure if it's safe.
-
New research indicates that a rapid test that uses self-collected vaginal swabs may be effective in diagnosing chlamydia.1 With its ability to deliver results in less than 30 minutes, the test, now in development, would give clinicians a same-day diagnostic and screening tool for chlamydial infection.
-
Review the number of sexually transmitted diseases (STDs) detected in your patient population over the last year.
-
Could a new combined oral contraceptive (OC) be available to U.S. women? Organon is conducting two Phase 3a trials for the first monophasic oral contraceptive containing estradiol (E2) and a new progestin, nomegestrol acetate (NOMAC).
-
Good news for your older female patients: Calcium, or calcium in combination with vitamin D, may prevent osteoporosis in those age 50 and older, results from a new meta-analysis show.
-
When men leave your family planning clinic, they may leave with a supply of condoms in hand. But do they leave with good information on the importance of correct, consistent condom use?
-
When you counsel on protection against HIV and other sexually transmitted diseases (STDs), where does the female condom fit into your message? While the female condom represents a woman-controlled form of protection against HIV and other STDs, its use has lagged in the United States since its introduction in 1993.
-
These three studies published back to back in the Journal of Infectious Diseases serve to better characterize HPV infection in heterosexual men.
-
-
The FDA has approved a non-halogenated nasal steroid for use in pediatric patients aged 6 to 12 years and adults. Ciclesonide is a prodrug that was previously approved for adults and adolescents but was not marketed. It's to be marketed by Nycomed US Inc. as Omnaris.